Roche announced  that it has received clearance from the US Food and Drug Administration (FDA) for the Accu-Chek Combo system for insulin pump therapy.

Pfizer Inc. announced that a Phase 3 randomized withdrawal design study for Lyrica ( pregabalin ) in patients with inadequately treated painful diabetic peripheral neuropathy ( pDPN ) did not meet its primary efficacy endpoint.

Novo Nordisk announced that the US Food and Drug Administration FDA) has approved to update the product label for Victoza ( liraglutide [ rDNA ] injection). Research data shows superior blood sugar control and weight reduction.

GlaxoSmithKline announced that topline results have been received from seven of the eight Harmony Phase III studies investigating the use of albiglutide in type 2 diabetes. Albiglutide is an investigational once weekly glucagon-like peptide-1 ( GLP-1 ) agonist.

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company BYETTA  ( exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos  ( pioglitazone ), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto  ( linagliptin / metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 ( DPP-4 ) inhibitor, linagliptin , and metformin .   

School-age children with diabetes face unique challenges and sometimes dangerous situations tied to their oftentimes unpredictable glucose levels.

The U.S. Department of Health and Human Services (HHS) is increasing awareness about a health plan for uninsured Americans with pre-existing conditions created by the Affordable Care Act.

Nearly 26 million Americans have diabetes, and another 79 million have prediabetes. That's about 30 percent of all Americans with a diabetes problem.